CURE’s leukemia page is a go-to resource for oncology news and updates in the world of leukemia Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in leukemia.
May 12th 2024
When I was diagnosed and treated for a recurrence of AML, I was given an abundance of statistical information through required medical expert orations and accredited literature.
FDA Approves New Drug Regimen for Acute Lymphoblastic Leukemia
December 21st 2018The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
FDA Approves Xospata and Companion Diagnostic Test for Leukemia Treatment
November 29th 2018The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.
FDA Approves First and Only Hedgehog Pathway Inhibitor for AML Treatment
November 21st 2018The Food and Drug Administration (FDA) approved Daurismo (glasdegib) plus low-dose cytarabine (LDAC) chemotherapy to treat older, newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy.
Drug Duo Granted Priority Review for CLL Treatment
October 17th 2018The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves New Agent for Hairy Cell Leukemia
September 13th 2018The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Relatives of Patients With Myeloid Blood Cancers May be at Two-Fold Risk for Disease
August 14th 2018Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.